{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:48Z","timestamp":1786119288093,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/fjc.0b013e3181bfb158","type":"journal-article","created":{"date-parts":[[2009,12,17]],"date-time":"2009-12-17T10:29:22Z","timestamp":1261045762000},"page":"543-551","source":"Crossref","is-referenced-by-count":13,"title":["Cardiovascular Effects of Torcetrapib in Conscious and Pentobarbital-anesthetized Dogs"],"prefix":"10.1097","volume":"54","author":[{"given":"James S","family":"Polakowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee C","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita J","family":"Kempf-Grote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennan C","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A","family":"Gintant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan F","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W","family":"Mittelstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210208","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0002-9149(92)90550-I","article-title":"Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study.","volume":"70","author":"Assmann","year":"1992","journal-title":"Am J Cardiol"},{"key":"R2-12-20210208","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"R3-12-20210208","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R4-12-20210208","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-12-20210208","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-12-20210208","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.ATV.0000118278.21719.17","article-title":"Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.","volume":"24","author":"Clark","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R7-12-20210208","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2006.06.067","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.","volume":"48","author":"Davidson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R8-12-20210208","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.ATV.0000256728.60226.77","article-title":"The failure of torcetrapib: was it the molecule or the mechanism?","volume":"27","author":"Tall","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R9-12-20210208","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14656566.9.6.875","article-title":"The failure of torcetrapib: is there a case for independent preclinical and clinical testing?","volume":"9","author":"Doggrell","year":"2008","journal-title":"Exp Opin Pharmacother"},{"key":"R10-12-20210208","doi-asserted-by":"crossref","first-page":"H238","DOI":"10.1152\/ajpheart.01181.2007","article-title":"Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.","volume":"294","author":"Banfor","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R11-12-20210208","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An improved method to correct the QT interval of the electrocardiogram for changes in heart rate.","volume":"22","author":"Van de Water","year":"1989","journal-title":"J Pharmacol Meth"},{"key":"R12-12-20210208","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archinte.160.8.1085","article-title":"Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients.","volume":"160","author":"Blacher","year":"2000","journal-title":"Arch Intern Med"},{"key":"R13-12-20210208","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/01.CIR.95.1.151","article-title":"Noninvasive assessment of the ventricular relaxation time constant () in humans by Doppler echocardiography.","volume":"95","author":"Scalia","year":"1997","journal-title":"Circulation"},{"key":"R14-12-20210208","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis.","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R15-12-20210208","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc Res"},{"key":"R16-12-20210208","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yrtph.2008.04.007","article-title":"Safety evaluation to support First-In-Man investigations. I: Kinetic and safety pharmacology studies.","volume":"51","author":"Baldrick","year":"2008","journal-title":"Regulatory Toxicol Pharmacol"},{"key":"R17-12-20210208","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.vascn.2008.05.007","article-title":"Safety and secondary pharmacology: successes, threats, challenges and opportunities.","volume":"58","author":"Valentin","year":"2008","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R18-12-20210208","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cca.2009.01.018","article-title":"Molecular mechanisms of pulmonary hypertension.","volume":"403","author":"Yildiz","year":"2009","journal-title":"Clin Chim Acta"},{"key":"R19-12-20210208","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1124\/dmd.108.022277","article-title":"Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.","volume":"36","author":"Prakash","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R20-12-20210208","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1124\/dmd.108.023176","article-title":"Pharmacokinetics, metabolism and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans.","volume":"36","author":"Dalvie","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R21-12-20210208","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/HCO.0b013e32832ac166","article-title":"The end of the road for CETP-inhibitors after torcetrapib?","volume":"24","author":"Joy","year":"2009","journal-title":"Curr Opin Cardiol"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005344-200912000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:30Z","timestamp":1786039890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005344-200912000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0b013e3181bfb158","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}